Abstract: The present invention provides new interferon &bgr; conjugates, methods of preparing such conjugates and the use of such conjugates in therapy, in particular for the treatment of multiple sclerosis.

Abstract: The present invention provides new interferon &bgr; conjugates, methods of preparing such conjugates and the use of such conjugates in therapy, in particular for the treatment of multiple sclerosis.

Abstract: The invention relates to a conjugate comprising an adiponectin polypeptide, and a first non-polypeptide moiety covalently attached to the adiponectin polypeptide, wherein the adiponectin polypeptide comprises an amino acid residue having an attachment group for said first non-polypeptide moiety, wherein said amino acid residue has been introduced in a position that in the parent adiponectin is occupied by a surface exposed amino acid residue.

Abstract: The invention relates to a conjugate exhibiting interferon &bgr; (IFNB) activity and comprising at least one first non-polypeptide moiety covalently attached to an IFNB polypeptide, the amino acid sequence of which differs from that of wildtype human IFNB in at least one introduced and at least one removed amino acid residue comprising an attachment group for said first non-polypeptide moiety. The first non-polypeptide moiety is e.g. a polymer molecule or a sugar moiety. The conjugate finds particular use in therapy. The invention also relates to a glycosylated variant of a parent IFNB polypeptide comprising at least one in vivo glycosylation site, wherein an amino acid residue of said parent polypeptide located close to said glycosylation site has been modified to obtain the variant polypeptide having an increased glycosylation as compared to the glycosylation of the parent polypeptide.

Abstract: Methods for producing polypeptide with altered immunogenicity or improved stability properties are disclosed.

Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.

Abstract: The present invention provides new interferon &bgr; conjugates, methods of preparing such conjugates and the use of such conjugates in therapy, in particular for the treatment of multiple sclerosis.

Abstract: The present invention relates to novel conjugates between polypeptide variants of protein C and a non-polypeptide moiety, such as PEG or sugar moieties. In particular, the present invention provides novel protein C conjugates having an increased resistance to inactivation by e.g. human plasma and &agr;1-antitrypsin. Consequently, such conjugates have an increased in vivo half-life. Preferred examples include protein C conjugates, wherein at least one additional in vivo N-glycosylation site has been introduced. The conjugates of the invention are useful for treating a variety of diseases, including septic shock.

Abstract: The present invention relates to novel conjugates between polypeptide variants of protein C and a non-polypeptide moiety, such as PEG or sugar moieties. In particular, the present invention provides novel protein C conjugates having an increased resistance to inactivation by e.g. human plasma and &agr;1-antitrypsin. Consequently, such conjugates have an increased in vivo half-life. Preferred examples include protein C conjugates, wherein at least one additional in vivo N-glycosylation site has been introduced. The conjugates of the invention are useful for treating a variety of diseases, including septic shock.

Abstract: The present invention relates to a single chain multimeric interferon &bgr; polypeptide comprising at least two monomers linked via a peptide bond or a peptide linker, wherein at least one of said monomers is an interferon &bgr; monomer comprising an amino acid sequence that differs from that of wildtype human interferon &bgr; in at least one introduced glycosylation site, methods of preparing such polypeptides or conjugates, and the use of such polypeptides in therapy, in particular for the treatment of multiple sclerosis.

Abstract: A method for antimicrobial treatment of microorganisms and/or viruses which involves treating the microorganisms and/or viruses with an effective amount of a fungal laccase and one or more enhancers in the presence of oxygen, the enhancers having the formula: 1

Abstract: The present invention relates to a method of designing laccase mutants with improved stability properties, which method is based on the hitherto unknown three-dimensional structure of Coprinus cinereus laccase.

Abstract: A method for antimicrobial treatment of microorganisms and/or viruses which involves treating the microorganisms and/or viruses with an effective amount of a fungal laccase and one or more enhancers in the presence of oxygen, the enhancers having the formula: wherein A, B and C are as defined in the specification.

Abstract: The present invention relates to a method of designing laccase mutants with improved stability properties, which method is based on the hitherto unknown three-dimensional structure of Coprinus cinereus laccase.

Abstract: The present invention relates to a method of designing laccase mutants with improved stability properties, which method is based on the hitherto unknown three-dimensional structure of Coprinus cinereus laccase.

Abstract: A purified peroxidase obtained from a strain of Myxococcus, having a molecular weight of about 40 kDA as determined by SDS-PAGE, which is stable up to 60.degree. C. for 2 hours without loss of activity, and retains activity at pH 10.5.

Abstract: The present invention relates to laccase mutants with improved stability properties, in particular to Myceliophthora and Scytalidium laccase variants.

Abstract: The present invention relates to a detergent composition, detergent additive as well as a method of oxidizing a substrate which comprises contacting the substrate with a composition which includes an enzyme selected from the group consisting of laccase, catechl oxidase, monophenol monooxygenase, and bilirubin oxidase and an enhancing agent.

Abstract: The invention relates to a process for providing a bleached look in the color density of the surface of dyed fabric, especialy cellulosic fabric such as denim, comprising use of a phenol oxidizing enzyme such as a peroxidase or a laccase, a hydrogen peroxide source and a phenothiazine or phenoxazine enhancing agent represented by formula (I).

Abstract: The present invention relates to a novel variant of peroxidase with improved stability at alkaline conditions, and a bleaching or detergent composition comprising the peroxidase variant.